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The classical pathway of complement plays multiple physiological roles including mod-
ulating immunological effectors initiated by adaptive immune responses and an essen-
tial homeostatic role in the clearance of damaged self-antigens. However, dysregulated
classical pathway activation is associated with antibody-initiated, inflammatory diseases
processes like cold agglutinin disease, acute intravascular hemolytic transfusion reaction
(AIHTR), and acute/hyperacute transplantation rejection.To date, only one putative classical
pathway inhibitor, C1 esterase inhibitor (C1-INH), is currently commercially available and
its only approved indication is for replacement treatment in hereditary angioedema, which
is predominantly a kinin pathway disease. Given the variety of disease conditions in which
the classical pathway is implicated, development of therapeutics that specifically inhibits
complement initiation represents a major unmet medical need. Our laboratory has iden-
tified a peptide that specifically inhibits the classical and lectin pathways of complement.
In vitro studies have demonstrated that these peptide inhibitors of complement C1 (PIC1)
bind to the collagen-like region of the initiator molecule of the classical pathway, C1q. PIC1
binding to C1q blocks activation of the associated serine proteases (C1s–C1r–C1r–C1s) and
subsequent downstream complement activation. Rational design optimization of PIC1 has
resulted in the generation of a highly potent derivative of 15 amino acids. PIC1 inhibits clas-
sical pathway mediated complement activation in ABO incompatibility in vitro and inhibiting
classical pathway activation in vivo in rats. This review will focus on the pre-clinical devel-
opment of PIC1 and discuss its potential as a therapeutic in antibody-mediated classical
pathway disease, specifically AIHTR.
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INTRODUCTION
Activation of the classical pathway of complement is mediated
via C1, a multimolecular complex composed of the recognition
molecule C1q and the associated serine proteases C1r and C1s
(1). IgM or clustered IgG serves as the principal ligand for C1q,
resulting in the sequential activation of C4 and C2 to form the
classical pathway C3-convertase leading to C3 and C5 activation.
This cascading activation sequence generates a number of inflam-
matory effector molecules designed to limit infection by invading
pathogens. Additionally, C1 plays an essential housekeeping role
by recognizing and clearing cellular debris, immune complexes,
altered self, and apoptotic cells (2) as well as identifying abnormal
structures such as beta-amyloid fibrils (3, 4) and the pathological
form of the prion protein (5, 6). The ability of this molecule to
distinguish self from non-self is critical for immune tolerance and
homeostasis (7).
Under normal circumstances, complement activation is tightly
controlled by a number of regulatory proteins to minimize host tis-
sue damage. However, aberrant activation of the classical, lectin,
or alternative pathways of complement leads to significant host
tissue damage in many inflammatory diseases (8). In the case of
the classical pathway of complement, irregular activation of this
pathway has been implicated in cold agglutinin disease (CAD)
(9), acute/hyperacute transplantation rejection (10), and other
inflammatory and autoimmune conditions (11). In the field of
hematology, inappropriate activation or dysregulated control of
complement activation plays a central role in hemolytic disease
processes such as acute intravascular hemolytic transfusion reac-
tion (AIHTR) (12), autoimmune hemolytic anemia (13), and
hemolytic disease of the newborn (14). In these disease processes,
preexisting antibodies, typically natural antibodies, bind to ery-
throcyte surface antigens initiating classical complement pathway
activation via C1 (15). Subsequent terminal complement cascade
activation leads to membrane attack complex (MAC) formation
on the erythrocyte surface and intravascular hemolysis. In the
case of an AIHTR (such as an ABO incompatible transfusion),
recipient serum containing antibody that specifically recognizes
antigens on the surface of the donor’s red blood cells (RBCs)
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FIGURE 1 | ABO incompatible destruction of RBCs by the classical
pathway of complement. In this example, transfused cells expressing A
antigen have been exposed to incompatible recipient serum containing
anti-A IgM. The bound IgM molecule is then recognized by serum
complement C1 complex. Upon binding to IgM, C1 activates the classical
pathway, resulting in complement deposition on the donor cell and eventual
clearance or lysis of host RBCs by the membrane attack complex (MAC).
For clarity, only C1 binding and MAC formation are illustrated here.
results in classical pathway mediated rapid intravascular hemoly-
sis of donor RBCs within minutes (Figure 1). Due to the rapidly
amplifying cascade driving this process, AIHTR frequently results
in shock, disseminated intravascular coagulation, acute renal fail-
ure due to hemoglobinuria, and death (16). To date, there are
no pharmacological interventions to treat the underlying mech-
anisms of this disease processes such that treatment is primarily
supportive (17, 18). Thus, there is a critical need for inhibitors of
the classical pathway that can block complement activation at the
level of C1 and prevent the avalanche of complement activation
at the initiation event of the cascade. In this review, we describe
the identification and characterization of a novel inhibitor of C1
termed peptide inhibitor of complement C1 (PIC1) and discuss
its potential as an anti-complement therapeutic for transfusion
medicine applications.
DISCOVERY AND CHARACTERIZATION OF PIC1
The findings that led to the discovery of the complement inhibitory
peptide PIC1 in our laboratory initially came from our research
program on human astrovirus capsid assembly. Below, we discuss
how PIC1 has evolved from a capsid protein of 787 amino acids to
a 15 amino acid peptide that is unique in nature.
HUMAN ASTROVIRUS COAT PROTEIN INHIBITION OF THE CLASSICAL
AND LECTIN PATHWAYS
Human astroviruses (HAstVs) are a major cause of diarrhea in
human infants (19). The virus replicates in intestinal epithelial
cells, but produces no inflammation in the intestinal tissues (20).
We showed in hemolytic complement assays that lysates made
from cell culture infected with HAstV serotypes 1, 2, 3, and 4
all strongly inhibited serum complement activation, >84% (21).
Human astrovirus type 1 (HAstV-1) is the most common serotype
worldwide (22). Recombinantly expressed HAstV-1 coat protein
(CP) was able to inhibit complement-mediated hemolysis>90%.
Subsequent testing showed that CP was able to inhibit the activa-
tion of C3, C5, and C5b-9 in serum, demonstrating that the gen-
eration of downstream effectors was inhibited (21). CP strongly
inhibited activation of the classical pathway and antibody-initiated
complement activation in a variety of systems, but had no signif-
icant effects on the alternative pathway. CP inhibited activation
of C1, as assayed by C1s activation, preventing the activation of
C4 in serum. Moreover, complement activation could be restored
with the addition of exogenous C1. CP bound to both the globu-
lar head regions and collagen-like regions (CLRs) of C1q, but had
higher affinity for the CLR, where the C1s–C1r–C1r–C1s tetramer
is nestled. C1s was displaced from intact C1 by CP, suggesting the
displacement of the cognate serine protease(s) is the likely mech-
anism of inhibiting C1 activation (23). CP also inhibited mannan
activation of MBL/MASP2 in human serum (23). MBL with a
point mutation that prevents binding to MASP2 (i.e., Lys55Gln
substitution) cannot bind CP, suggesting that CP competes for the
cognate serine protease binding site of MBL, similar to C1 (23).
PIC1 INHIBITION OF ANTIBODY-INITIATED COMPLEMENT ACTIVATION
Within the amino acid sequence of the CP molecule, we identified
a 60-residue region of homology corresponding to human neu-
trophil peptide 1 (HNP-1) (Figure 2). HNP-1 has been identified
by other investigators as an inhibitor of C1 and MBL (24, 25).
From the region of homology found within the CP molecule, two
synthetic peptides were generated of 30 residues each (Figure 2).
The PIC1 derivative coat protein peptide 1 (CPP1) inhibited the
binding of CP to C1q and inhibited C1 activation, as assayed by C1s
cleavage, suggesting a similar mechanism of action as the parent
compound (Table 1) (26). Coat protein peptide 2 did not demon-
strate either of these properties, indicating that the active region
of CP could be successfully narrowed to a small peptide construct.
A further derivative of CPP1 with an alanine substitution at posi-
tion 23 (E 23A), as indicated by bold red in Table 1, demonstrated
superior inhibitory activity to CPP1 (26). Additional truncations
demonstrated that removing the central region of CPP1 (∆8–22)
yielded a functional peptide of 15 residues (Table 1) (26). The∆8–
22 construct inhibited antibody-initiated complement activation
to a greater degree than CPP1,as demonstrated in hemolytic as well
as C4 activation assays and similar to the parent CP. As a smaller
peptide with similar potency to the E23A construct, ∆8–22 still
had minimal effect on the alternative pathway (26).
FURTHER OPTIMIZATION OF PIC1 DERIVATIVES
In an attempt to further optimize the PIC1 ∆8–22 derivative
and improve its solubility properties, the peptide sequence was
rearranged such that most of the hydrophobic residues were placed
at the N terminus and the hydrophilic residues were placed at the
C terminus. The rearranged PIC1 derivative was termed polar
assortant (PA) (Table 1) and demonstrated superior complement
inhibitory activity to all other derivatives previously reported (27).
A deletion analysis of PA showed that loss of one amino acid
residue from the N or C terminus destroyed inhibitory activity
suggesting that 15 residues may be the optimal length of this
PIC1 derivative (27). An alanine scan and a scan substituting each
residue of PA with a negative or positively charged amino acid (40
total substitutions analyzed) revealed that PA was the most potent
PIC1 analog capable of inhibiting classical pathway mediated com-
plement activation [Ref. (27), and data not shown]. PA was also
demonstrated to specifically bind to the CLR of C1q by ELISA and
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FIGURE 2 | Alignment of CP with the HNP-1 molecule using ClustalW analysis. Homologous residues are identified as follows: identical (*), conserved (:),
and semi-conserved (.) residues. CPP1 and CPP2 were synthesized based upon this alignment.
Table 1 | PIC1 derivatives.
Peptide Peptide sequence (N→C) Classical pathway
inhibition values
using 0.77mM
peptide (%)
CPP1 PAICQRATATLGTVGSNTSGTTEIEACILL 50
E23A PAICQRATATLGTVGSNTSGTTAIEACILL 80
∆8–22 PAICQRAEIEACILL 70
PA IALILEPICCQERAA 85
bound to purified C1q with a mean equilibrium dissociation con-
stant (KD) of 33.3 nM as determined by surface plasmon resonance
(27). It has been previously demonstrated by surface plasmon res-
onance that immobilized C1q binds to its cognate serine proteases
(C1s–C1r–C1r–C1s) with a KD of 2.72 nM (28). The binding of
PA to C1q with similar affinity for C1s–C1r–C1r–C1s (i.e., nM
range) is consistent with our hypothesis that the PIC1 peptides
may function by displacing, at least partially, C1s–C1r–C1r–C1s
from the CLR of C1q thereby changing the optimal conformation
of the serine protease tetramer and preventing autoactivation. A
hypothetical model of the mechanism by which PIC1 derivatives
inhibit C1 and MBL activation is presented in Figure 3.
The PIC1 PA derivative, to our knowledge, is unique in nature
(Figures 4A,B) as it does not possess any identifiable similar-
ity with known proteins by NCBI blast search. It is 15 residues
in length with a pI of 4.53 and a molecular weight of 1643 Da.
While our data to date suggest that PA disrupts the interaction of
C1s–C1r–C1r–C1s and MASP2 with the CLR of C1q and MBL,
respectively, the precise molecular details of this interaction are
unclear. As mentioned above, astrovirus CP does not bind an MBL
mutant in which the lysine residue that are critical for MASP2
binding to the CLR of MBL has been substituted with another
residue (23). This suggests that PIC1 derivatives may bind to the
same critical lysine residue on the MBL and C1q molecules. While
it is obvious to suggest that this reactive lysine residue may interact
with either of the negatively charged glutamic acid residue on PA
at positions 6 and 12 (Figures 4A,B), substitution of either of these
residues individually or together with alanine had no detrimen-
tal effect on PA inhibitory activity (27), suggesting that binding
of these derivatives to C1q was not compromised. It is highly
conceivable that PIC1 may bind to the C1q/MBL CLR through
other interactions such as hydrophobic and hydrogen bonding.
Due to the large number of hydroxylated residues that exist in
the CLR of C1q and MBL, extensive hydrogen bonding with PIC1
FIGURE 3 | A model of PIC1 interfering with the normal association of
C1q/MBL with their cognate serine proteases (C1s–C1r–C1r–C1s/
MASPs). Our data suggest PIC1 functionally disrupts the C1s–C1r–C1r–
C1s/MASPs interaction with collagen-like region (CLR) of C1q/MBL,
respectively. By virtue of PIC1 binding to this region of the CLR, the serine
proteases are hypothesized to be in suboptimal conformation for
autoactivation and initiation of the classical and/or lectin pathways of
complement.
is an entirely feasible mechanism by which PIC1 may bind these
molecules. Studies of PIC1 interaction with C1q using protein
footprinting techniques combined with mass spectrometry are
currently underway in our laboratory. The recent development
of a system to produce the A, B, and C chains of C1q recombi-
nantly (29) also provides a means to produce specific mutations
in the C1q molecule, which would provide an invaluable resource
in mapping the regions of interaction between C1q and PIC1. Pre-
cise details on the interaction of PIC1 with C1q and MBL would
also benefit from structural studies utilizing X-ray crystallography
and/or nuclear magnetic resonance imaging to directly visualize
structural interactions. A hypothetical model of PIC1 PA is shown
in Figure 4C.
PRE-CLINICAL DEVELOPMENT OF PIC1
PIC1 INHIBITION OF ABO INCOMPATIBILITY IN VITRO AND IN VIVO
INHIBITION OF COMPLEMENT
To evaluate the ability of PIC1 derivatives to inhibit ABO mediated
RBC lysis, two PIC1 analogs were tested in an in vitro model of
ABO incompatibility. E23A and an acetylated version of PA were
both demonstrated to dose-dependently inhibit lysis of human AB
RBCs incubated with human O serum in a modified hemolytic
assay (27). Acetylated PA has identical inhibitory activity com-
pared to unmodified PA (27). To preliminarily assess the in vivo
complement suppression profile of these two derivatives, 20 mg
of E23A and an acetylated version of PA were injected into 250 g
male Wistar rats. Both peptides were able to cross the species bar-
rier and inhibit serum complement activity in these animals as
assessed by hemolytic assay using serum purified from the blood
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FIGURE 4 | Peptide inhibitors of complement C1 derivative PA. (A)The 15 residue PA molecule is made up of 9 hydrophobic (red), 3 polar/charged (blue),
and 3 intermediary (green) amino acid residues. (B) A linear version of the PA molecule illustrating the amino acid side chains. (C) A structural model of PA.
(B,C) Created in MarvinView.
ex vivo. Administration of the acetylated PA molecule resulted
in in vivo complement suppression up to 24 h post-injection
(27). These findings demonstrate that PIC1 molecules have excel-
lent potential for pre-clinical testing in small animal models of
antibody-initiated complement disease.
DEVELOPMENT OF A RAT MODEL OF AIHTR
A simple yet elegant model of complement-mediated AIHTR in
rodents has been previously reported (30, 31). In this mouse
model, developed in the laboratory of Dr. K. Yazdanbakhsh (32–
34), human RBCs fluorescently labeled with the dye PKH-26 were
transfused i.v. via tail vein and complement-mediated hemoly-
sis of the transfused cells analyzed. In this mouse strain, natural
antibodies directed against antigens on the human RBCs initiated
complement activation leading to rapid lysis over 120 min. Soluble
complement receptor 1 (sCR1) or derivatives of this molecule were
demonstrated to temporarily inhibit hemolysis as well as C3 and
C4 deposition on the transfused human RBCs (32). In the past few
years, sCR1 (also known as TP-10) has been explored in clinical
trials of human diseases; however, these trials have been discon-
tinued for various reasons. In order to test PIC1 in a pre-clinical
model of AIHTR, we have recently developed a Wistar rat trans-
fusion model (35). The rationale for utilizing the rat is threefold:
(i) the larger size of the rat provides adequate blood volume to
perform multiple blood draws for analysis post-transfusion, (ii)
extracted mouse serum is notoriously difficult to use in ex vivo
hemolytic assays (36), and (iii) while human RBCs are identical
in size to rat RBCs, they are twice the size of mouse RBCs and
thus may have difficulty in transiting the narrow capillaries of the
mouse (37). Wistar rats are also thought to have natural antibodies
against human erythrocytes (38).
To establish this model, we first determined in vitro that Wistar
rat serum lysed human RBCs in an antibody-initiated, classical
complement pathway dependent manner by utilizing comple-
ment sufficient or complement-deficient Wistar rat serum in the
presence and absence of naturally occurring anti-human RBC
antibody (35). This was achieved by coating human AB RBCs
with complement-deficient Wistar rat serum that contains anti-
bodies to the human RBCs. When the antibody coated RBCs were
exposed to antibody deficient, complement sufficient Wistar rat
serum, the RBCs were lysed in a dose-dependent manner (i.e.,
increasing the amount of antibody on the surface of the RBCs
increased lysis by rat serum). Thus, lysis required both anti-human
erythrocyte antibodies from the Wistar rat serum and activat-
able rat complement. Using various buffers, we demonstrated that
the lysis of the RBC in vitro was due to classical pathway acti-
vation. To study the role of complement in acute intravascular
hemolysis in vivo, Wistar rats were treated either with or with-
out cobra venom factor (CVF) to deplete complement activity.
PHK-26 labeled or unlabeled human AB RBCs were then injected
Frontiers in Immunology | Molecular Innate Immunity August 2014 | Volume 5 | Article 406 | 4
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Sharp et al. PIC1 inhibits classical complement pathway
into both groups of rats, followed by serial blood draws up to
2 h. Venous blood clearance and lysis of transfused RBCs at each
time point was measured by flow cytometry (FITC labeled anti-
human CD235a was used to detect unlabeled human cells) and
spectrophotometry for free hemoglobin. Transfusion of human
RBCs into rats showed significantly less hemolysis in the CVF
group versus untreated group for both PHK-26 labeled and unla-
beled cells by both flow cytometry and spectrophotometry (35).
RBC sequestration was determined in the liver, spleen, and kidney
by immunohistochemistry 2 h post-transfusion and demonstrated
no quantitative difference for extravascular RBCs in the tissues
between the two groups for the liver and spleen (35). However,
intravascular human RBCs in the kidney glomeruli were differ-
ent between the two groups, consistent with the flow cytometry
and spectrophotometry data. Given these findings, we believe this
simple rat model is ideal for testing novel inhibitors of classical
pathway activation such as PIC1 for the prevention and treatment
of AIHTR. Experiments to test PIC1 in this model are currently
underway in our laboratory.
COMPLEMENT INHIBITORS FOR TRANSFUSION MEDICINE
APPLICATIONS
Acute hemolytic transfusion reactions occur in almost one-fifth
of total transfusions, with life-threatening reactions in approxi-
mately 0.5% (39). The clinical presentation of acute hemolytic
transfusion reactions is broad, from the transfusion recipient who
exhibits only mild and transitory signs and symptoms, to more
serious cases, with shock, disseminated intravascular coagulation,
renal failure, and death. The most severe reactions result from
transfusion of incompatible RBCs from donor to recipient lead-
ing to rapid intravascular complement-mediated hemolysis. As
there are no specific interventions to directly mitigate the effects
of acute hemolytic transfusion reaction, only safeguard measures
to reduce the risk of an incompatible transfusion are currently
employed. Although current safeguards make ABO incompati-
ble transfusions rare in the developed world, AIHTR remains a
very high-risk threat for patient populations receiving frequent
transfusions. Specifically, individuals with sickle cell disease and
severe thalassemias requiring frequent transfusions become “diffi-
cult to cross match” due to the accumulation of antibodies against
minor antigenic determinants on erythrocytes. In situations of
life-threatening anemia (i.e., inadequate oxygen carrying capac-
ity) these patients are not infrequently transfused with the “least
incompatible” erythrocytes, because some degree of agglutination
occurs with the cross match of all available units. These trans-
fusions are extremely high risk for causing AIHTR, but must be
done because the alternative is death by shock. An ideal thera-
peutic intervention for these individuals would be prophylactic
treatment prior to transfusion with “least incompatible” erythro-
cytes, to decrease the risk of AIHTR. The ability to prevent AIHTR
for these patients remains an important unmet medical need. As
we have described in this review, the classical pathway of comple-
ment plays a central role in AIHTR. Thus, therapeutic inhibition
of this system presents a viable strategy to mitigate and prevent
AIHTR. Below, we discuss various complement inhibitors, both
marketed and in development, and their potential for transfusion
medicine and other blood disorders.
MARKETED COMPLEMENT INHIBITORS
C1-inhibitor
C1 esterase inhibitor (C1-INH) is a serine protease inhibitor that
was initially demonstrated to regulate the C1 complex by bind-
ing and releasing the C1s–C1r–C1r–C1s tetramer from C1q after
activation has occurred (40, 41). C1-INH has a broad specificity
and also regulates the MBL–MASP2 complex of the lectin path-
way of complement as well as serine proteases of the fibrinolytic,
coagulation, and kinin systems. C1-INH has been successfully
marketed as a replacement therapy for hereditary angioedema
(HAE) in which the afflicted individual makes inadequate or defec-
tive C1-INH protein. While it is appreciated that HAE is primarily
a kinin disease (42), C1-INH has been demonstrated to inhibit
complement-mediated disease in several animal models and is
currently in clinical trials for trauma and kidney transplantation
[reviewed in Ref. (43)]. Recently, a study reported high dose C1-
INH concentrate could prevent complement-mediated lysis of
RBC in an elderly patient with autoimmune hemolytic anemia
(43). While application of C1-INH has potential in complement-
mediated disease, aside from HAE, super-physiological amounts
of C1-INH are required to see a clinical effect when C1-INH is
normally expressed in humans. Infusing high concentrations of
C1-INH is of potential concern given C1-INH’s promiscuous inhi-
bition of other serine proteases (43); however, such high doses may
be tolerable in an acute intervention setting. While recombinant
C1-INH is now available, the purified version of human C1-INH is
a blood product requiring extensive purification from large num-
bers of donors, resulting in an extremely expensive medication that
still carries a residual risk of transmitting blood-borne pathogens.
The results of the two clinical trials to determine the efficacy of
C1-INH are eagerly awaited.
Nafamostat
Nafamostat is a synthetic serine protease inhibitor of C1s and other
proteases currently marketed for pancreatitis. As is the case with
C1-INH, nafamostat inhibits serine proteases other than C1s; thus,
it is unclear if its clinical effects can be attributed to suppression
of the complement system (44) as opposed to its known anticoag-
ulant properties (45). Currently, nafamostat is only approved in a
limited market (Japan and Korea). Other small molecule inhibitors
of C1s have also been characterized (46); however, to our knowl-
edge, the role of these inhibitors in transfusion-related indications
has not been reported.
Eculizumab
Eculizumab is a highly specific, humanized monoclonal anti-
body that inhibits activation of C5 by the C5 convertase pre-
venting C5a release and MAC formation. Eculizumab has been
marketed for the orphan disease paroxysmal nocturnal hemo-
globinuria (PNH) preventing the intravascular lysis of RBC that
lacks the membrane bound complement regulators CD55 and
CD59 (47). Eculizumab is also marketed for atypical hemolytic
uremic syndrome (aHUS) (48) and is currently in clinical tri-
als for other indications (44). Eculizumab has also been reported
to reverse antibody-mediated complement activation in a case of
ABO incompatible kidney and pancreas transplantation (49), and
kidney-alone transplantation (50) as well as other off-label uses.
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Eculizumab is very effective for individuals for PNH; however,
it is currently one of the most expensive drugs on the market
as a result of its high cost of production and its orphan sta-
tus. Additionally, since it blocks complement activation at the
level of C5, patients utilizing this drug are at increased risk of
invasive meningococcal infections and therefore require vacci-
nation. Another drawback for antibody-mediated complement
disease indications is that eculizumab acts downstream of C3 and
therefore cannot prevent classical pathway generated C3 activation
products such as C3a formation or C3b/iC3b opsonization of host
cells (e.g., CR1/CR3-mediated clearance of C3b/iC3b-coated RBC
in the liver and spleen). This may limit eculizumab’s potential for
antibody-mediated, transfusion medicine related indications.
COMPLEMENT INHIBITORS CURRENTLY IN DEVELOPMENT
A number of complement inhibitors are currently in various stages
of pre-clinical and clinical development [please see Ref. (44) for a
thorough review]. As one would expect, the compounds currently
under pharmaceutical development target a variety of molecules of
the complement system including effector molecules and receptor
proteins (C5aR, C3, C5, etc.). Given the ubiquitous role of comple-
ment in a variety of diseases, these inhibitors have a wide number
of indications from transplantation to cancer. Most of these com-
pounds are of the following classes: protein, antibody, or small
molecule. Interestingly, there are currently only two peptide com-
pounds in pharmaceutical development. One of the peptides that
shows great promise is compstatin, a cyclical peptide that binds
C3 preventing C3 activation of all three complement pathways
(51). Analogs of compstatin are in various stages of pre-clinical
and clinical development for indications such as age-related mac-
ular degeneration (AMD), PNH, aHUS, dense deposit disease
(DDD), transplantation, and hemodialysis (44). Recently, comp-
statin analogs have been demonstrated to inhibit hemolysis of
PNH RBCs in an in vitro system (52), indicating that compstatin
may be useful in this RBC disorder. Additionally, compstatin has
a significant theoretical advantage over eculizumab by virtue of
its ability to block C3 cleavage and thus preventing C3b/iC3b
opsonization of RBC leading to extravascular sequestration and
hemolysis. While pharmacological blockade of C3 by compstatin
positions this molecule as a potent inhibitor of complement, com-
plete shutdown of this critical arm of innate immunity may lead
to an increased risk of infection, whether this is a potential issue
will become evident as clinical testing of compstatin progresses.
Recently, a mouse monoclonal antibody that targets C1s,
known as TNT003, has been demonstrated to prevent comple-
ment deposition and RBC destruction via phagocytosis in an
in vitro assay of CAD (53). TNT003 is currently under clinical
development by True North Therapeutics, Inc., as a first-in-class
compound designed to specifically inhibit the classical comple-
ment pathway. Dosing of TNT009, the humanized monoclonal
analog of TNT003, in cynomolgus monkeys demonstrated that a
single i.v. injection at 30 mg/kg inhibited the in vivo generation
of C4a, as determined by ELISA. Ex vivo analysis of serum taken
from animals receiving this single dose inhibited the hemolysis of
IgM-coated sheep RBCs and the deposition of C3b on these cells,
as assayed by FACS (54). TNT009 is expected to undergo phase
1 clinical trials in 2015 with an umbrella trial in Europe to test
the efficacy of TNT009 in multiple complement disorders (54).
The efficacy of TNT009 in clinical trials will be exciting to watch
unfold.
PEPTIDE INHIBITORS OF COMPLEMENT C1
The fact that several complement inhibitors are currently in pre-
clinical and clinical development is a testament to the central role
that complement plays in a variety of inflammatory disorders.
While the classical pathway of complement instigates antibody-
mediated destruction of human RBCs in AIHTR, there is currently
no therapeutic treatment for this condition. As outlined in this
article, we propose that PIC1 might be an ideal molecule to prevent
and treat AIHTR for the following reasons: (i) PIC1 inhibits at the
level of the first complement component of classical pathway, C1.
Inhibiting classical pathway activation at this step would prevent
complement activation at initiation, thus, preventing amplifica-
tion and downstream complement effector molecule generation
(C3a, C5a, MAC, etc.) (Figure 5). (ii) PIC1 binds to the CLR of C1q
and MBL. This is opposed to C1-INH and other small molecule
serine protease inhibitors, which are known to non-specifically
inhibit serine proteases outside of the complement system. Given
that PIC1 possesses a differential mechanism of interaction with
C1q that does not involve binding to catalytic sites of serine pro-
teases, a higher specificity is expected. (iii) PIC1 does not inhibit
the critical immune surveillance functions of the alternative and
terminal complement pathway. While inhibitors such as comp-
statin can potently inhibit C3, effectively shutting down all three
complement pathways, this has the potential to predispose individ-
uals to an increased risk of infection. This has been documented
for eculizumab that inhibits C5a formation and thus terminal
pathway activation increasing the risk of infection by neisserial
pathogens. (iv) PIC1 is unique in nature. This is opposed to C1-
INH and soluble versions of known complement regulators that
are produced endogenously in humans. Thus, molecules such as
C1-INH and sCR1 may theoretically require very high doses to
achieve a clinical effect. This remains to be determined, however,
especially as concerns sCR1, which by virtue of its presence in
FIGURE 5 | Recognition of RBC antigens on recipient cells by host
derived natural antibodies initiating classical complement via C1
leading to opsonization of host cells with C3b, anaphylatoxin C5a
recruitment and activation of neutrophils, and cell lysis by membrane
attack complex (MAC) pores. PIC1 blocks C1 activation at the first step of
the amplification cascade.
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solution may have additional effects compared to the endogenous
membrane bound form. C1-INH and sCR1 appear efficacious in
pre-clinical animal models; their efficacy in human trials is cur-
rently under evaluation. (v) PIC1 is cheap and easy to produce
by virtue of it being a synthetic small peptide. This is in contrast
to C1-INH and eculizumab, which are large molecules requiring
extensive purification and high production costs. Both these mol-
ecules are currently in the top five most expensive drugs in the
marketplace for their orphan disease indications, HAE (C1-INH),
and eculizumab (PNH and aHUS) (55).
A potential concern for therapeutic inhibition of the classical
complement pathway with molecules such as PIC1 or TNT003 is
that long-term, systemic inhibition of C1 in humans could pose a
risk for developing systemic lupus erythematosus (SLE). Humans
lacking functional C1q have been demonstrated to acquire SLE
due to the critical role of the classical pathway in maintaining
homeostasis through the clearance of cellular debris and immune
complexes (7). In the context of an acute disease target such as
AIHTR, classical pathway inhibition would not be expected to
be a major concern for development of SLE. However, systemic,
long-term use of classical pathway inhibitors for chronic disease
processes would need to be carefully scrutinized in this regard.
Further development of PIC1 is necessary to test this com-
pound in animal models of classical pathway mediated disease
such as AIHTR. To this end, a high potency, water soluble PIC1
derivative has been identified and dose ranging studies in rats
are currently underway. Important parameters such as pharmaco-
dynamics, pharmacokinetics, and toxicity of this derivative will
be established in these studies. Next, proof-of-concept experi-
ments in the rat model of AIHTR will be performed. Extended
dosing and toxicity studies in rats and in a second species (e.g.,
cynomolgus monkeys) will then need to be completed. This
will set the stage for submission of an investigational new drug
(IND) application to the FDA under an orphan drug designation.
This approach has been successfully utilized for the complement
inhibitors eculizumab and C1-INH.
In the US, death from acute hemolytic transfusion reactions
has decreased significantly due to numerous safety checks; how-
ever, accidental transfusion of incompatible blood between donor
and recipient continues to occur due to failure of screening tests
or human error (56). Ensuring safe and compatible blood prod-
ucts can be particularly challenging in certain instances such as
during emergencies, in a mass casualty setting, or when the sup-
ply of blood is limited. Moreover, patients who require frequent
blood transfusions may develop multiple antibodies against minor
determinants on RBC surfaces decreasing the likelihood that com-
patible blood can be rapidly identified (56). This is particularly
true for patients with sickle cell disease and other individuals suf-
fering from severe chronic anemia requiring many transfusions
over their lifetime leading to their development of a wide range
of alloantibodies against numerous minor and major erythrocyte
determinants (15, 16, 57). The development of these alloantibod-
ies can progress to the point where compatible blood may not
be identified in a timely manner, requiring the use of a “least
incompatible” RBC unit. Different therapies have been adopted
in attempts to minimize the risk from these “least incompatible”
units; for example, a “mini-transfusion” challenge can be utilized
to try to identify those units, which may lead to a life-threatening
complement-mediated acute intravascular hemolytic event before
the entire unit is transfused (18). Red cell antigen-sensitized
patients, such as those with sickle cell disease or thalassemia, con-
stitute a tremendous challenge for clinicians and the transfusion
service particularly in the emergent setting (58). Given the acute
hemolysis and hemoglobinemia already occurring for sickle cell
disease patients suffering a vasoocclusive crisis, the high risk for
worsening their clinical condition with additional AIHTR hemoly-
sis is especially worrisome. In this type of situation, pre-treatment
with PIC1 would minimize the risk of AIHTR for sickle cell disease
patients meeting a major unmet medical need in an under-served
population.
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